

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Secukinumab for treating ankylosing spondylitis after  
inadequate response to non-steroidal anti-inflammatory  
drugs or TNF-alpha inhibitors**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equalities issues were raised by consultees or scoping workshop attendees
--

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Not applicable
----------------

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

Not applicable
----------------

- |  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

Issue date: November 2015

No

**Approved by Associate Director (name):** Janet Robertson

**Date:** 05/10/2015